Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rituximab to Prevent Recurrence of Proteinuria in Kidney Transplant for FSGS
NCT01164098Phase 3Terminated
- Start
- Feb 2012
- Primary completion
- Oct 2016
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of rituximab in focal segmental glomerulosclerosis (FSGS) (2 arms). Primary endpoint: Urine Protein/Creatinine Ratio. Started Feb 2012; status: terminated.
02
Drugs
rituximab
03
Conditions
focal segmental glomerulosclerosis (FSGS)
Beyond the preview
Go deeper on NCT01164098.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01164098.